Zacks: Landauer Inc. (LDR) Given $42.67 Consensus Price Target by Brokerages
Shares of Landauer Inc. (NYSE:LDR) have been given an average broker rating score of 3.67 (Sell) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong sell recommendation and two have given a hold recommendation to the company. Landauer’s rating score has improved by 8.3% from 90 days ago as a result of a number of analysts’ upgrades and downgrades.
Brokerages have set a 12 month consensus price objective of $42.67 for the company and are forecasting that the company will post $0.29 earnings per share for the current quarter, according to Zacks. Zacks has also given Landauer an industry rank of 112 out of 265 based on the ratings given to related companies.
Several equities analysts have commented on the company. Zacks Investment Research lowered Landauer from a “buy” rating to a “hold” rating in a research report on Tuesday. Sidoti lowered Landauer from a “buy” rating to a “neutral” rating and set a $52.00 price objective for the company. in a research report on Tuesday, August 16th. Finally, Hilliard Lyons lowered Landauer from a “neutral” rating to an “underperform” rating in a research report on Friday, July 1st.
Several institutional investors have recently modified their holdings of LDR. Royce & Associates LP increased its position in shares of Landauer by 6.2% in the first quarter. Royce & Associates LP now owns 1,122,543 shares of the company’s stock valued at $37,122,000 after buying an additional 65,814 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Landauer by 6.0% in the second quarter. Vanguard Group Inc. now owns 771,711 shares of the company’s stock valued at $31,764,000 after buying an additional 43,370 shares during the last quarter. BlackRock Fund Advisors increased its position in shares of Landauer by 2.7% in the second quarter. BlackRock Fund Advisors now owns 633,292 shares of the company’s stock valued at $26,066,000 after buying an additional 16,800 shares during the last quarter. Chartwell Investment Partners LLC bought a new position in shares of Landauer during the second quarter valued at $20,161,000. Finally, BlackRock Advisors LLC increased its position in shares of Landauer by 0.8% in the second quarter. BlackRock Advisors LLC now owns 315,499 shares of the company’s stock valued at $12,986,000 after buying an additional 2,394 shares during the last quarter. Hedge funds and other institutional investors own 86.34% of the company’s stock.
Shares of Landauer (NYSE:LDR) opened at 43.97 on Tuesday. The firm’s 50-day moving average is $45.29 and its 200 day moving average is $40.66. The stock has a market capitalization of $422.24 million, a P/E ratio of 23.77 and a beta of 1.08. Landauer has a 12-month low of $26.99 and a 12-month high of $49.74.
Landauer (NYSE:LDR) last announced its quarterly earnings data on Monday, August 8th. The company reported $0.58 EPS for the quarter, beating the consensus estimate of $0.39 by $0.19. The business earned $37.90 million during the quarter, compared to analyst estimates of $35.24 million. Landauer had a return on equity of 102.93% and a net margin of 11.63%. On average, equities research analysts forecast that Landauer will post $1.76 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Wednesday, October 5th. Stockholders of record on Friday, September 16th were issued a dividend of $0.275 per share. The ex-dividend date was Wednesday, September 14th. This represents a $1.10 annualized dividend and a dividend yield of 2.50%. Landauer’s payout ratio is presently 59.14%.
Landauer, Inc (Landauer) is a provider of technical and analytical services to determine occupational and environmental radiation exposure. The Company is a domestic provider of outsourced medical physics services and a provider of radiology related medical products. It operates in three business segments: Radiation Measurement, Medical Physics and Medical Products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Landauer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Landauer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.